NCT03764553 (LyRICX) is a Phase 2 clinical trial of Liposomal Irinotecan in Esophageal Cancer, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Who is sponsoring NCT03764553?

NCT03764553 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

What drugs are being tested in NCT03764553?

Interventions in NCT03764553: Liposomal Irinotecan, Carboplatin, Capecitabine, Oxaliplatin, 5-fluorouracil, Leucovorin.

What condition does NCT03764553 study?

NCT03764553 studies Esophageal Cancer.

Is NCT03764553 still recruiting?

NCT03764553 is currently active, enrolled. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT03764553: LyRICX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Active, enrolled Phase 2 Last updated 7 April 2026

What this trial tests

Phase 2 trial testing Liposomal Irinotecan in Esophageal Cancer in 320 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 May 2019

Primary endpoint
31 July 2025

1 July 2026

Quick facts

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	320
Start date	1 May 2019
Primary completion	31 July 2025
Estimated completion	1 July 2026
Sites	34 locations across Netherlands

Drugs / interventions tested

Liposomal Irinotecan
Carboplatin (Carboplatin) — full drug profile →
Capecitabine (capecitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
5-fluorouracil
Leucovorin (leucovorin) — full drug profile →

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

18 and older, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, open label, randomized phase II trial for patients with previously untreated metastatic or locally advanced esophagogastric cancer, using a pick the winner design to identify the best combination therapy in terms of progression free survival and neurotoxicity.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, et al · · 2020 · cited 179× · PMID 32002302 · DOI 10.1080/2162402x.2019.1703449
Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
Dijksterhuis WPM, Verhoeven RHA, Slingerland M, Haj Mohammad N, et al · · 2020 · cited 32× · PMID 31340065 · DOI 10.1002/ijc.32580
Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment.
Vivarelli S, Candido S, Caruso G, Falzone L, et al · · 2020 · cited 29× · PMID 33291603 · DOI 10.3390/cancers12123636
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
The microbiome in pancreatic diseases: Recent advances and future perspectives.
Ammer-Herrmenau C, Pfisterer N, Weingarten MF, Neesse A. · · 2020 · cited 23× · PMID 32703080 · DOI 10.1177/2050640620944720
Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs - is it a new perspective for personalized treatment of cancer patients?
Kaźmierczak-Siedlecka K, Bulman N, Ulasiński P, Sobocki BK, et al · · 2023 · cited 7× · PMID 37985748 · DOI 10.1080/19490976.2023.2281017
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.
Tsukamoto Y, Hirashita Y, Shibata T, Fumoto S, et al · · 2023 · cited 3× · PMID 37627132 · DOI 10.3390/cancers15164104

Verify or expand the search:

Other trials of Liposomal Irinotecan

Trials testing the same drug.

NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
NCT07474103 — SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC · NA · recruiting
NCT07104604 — Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capeci · Phase 1 · recruiting
NCT05255666 — Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) · Phase 2 · withdrawn
NCT05382559 — A Study of ASP3082 in Adults With Advanced Solid Tumors · Phase 1 · recruiting

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials

Trials by the same sponsor.

NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03764553 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03764553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing